CRISPR Therapeutics AG filings document operating results, pipeline disclosures and capital-structure matters for a Swiss biopharmaceutical company developing gene-based medicines. Form 8-K reports furnish quarterly and annual financial results, business highlights for CASGEVY and investigational programs, clinical and regulatory updates across cardiovascular, autoimmune, immuno-oncology and regenerative medicine, and material-event disclosures.
The filing record also includes proxy materials covering shareholder voting and executive compensation, shelf-registration and prospectus-supplement disclosures for common-share offerings, and material definitive agreements for convertible senior notes due 2031. These filings describe common shares, equity financing mechanics, debt terms, governance matters and business disclosures tied to the company’s CRISPR/Cas9, LNP, CAR-T and siRNA platforms.
CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni reported compensation-related share activity. On March 10, 2026, 19,250 restricted stock units were exercised into 19,250 Common Shares at $0.00 per share, reflecting vesting of part of a prior equity award.
On March 11, 2026, 9,798 Common Shares were sold at $52.80 per share. A footnote explains this amount was required to be sold to cover tax withholding tied to the RSU vesting under the company’s RSU Settlement Policy, and therefore did not represent a discretionary trade. After these transactions, Kulkarni directly held 235,558 Common Shares.
CRISPR Therapeutics AG is raising capital through a private offering of $550 million aggregate principal amount of convertible senior notes due 2031, sold to qualified institutional buyers. The offering was upsized from a previously proposed $350 million.
The notes carry an effective coupon of 1.125%, increased to 1.7308% to offset anticipated Swiss withholding tax, and mature on March 1, 2031 unless earlier converted, redeemed or repurchased. They are initially convertible at 13.0617 common shares per $1,000 principal amount, implying a conversion price of about $76.56 per share, a roughly 45% premium to the $52.80 share price on March 10, 2026. CRISPR Therapeutics estimates net proceeds of approximately $536.3 million, or $585.2 million if the purchasers’ option is fully exercised, and plans to use the funds for general corporate purposes.
CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni reported RSU vesting and a related share sale. On February 18, 2026, he acquired 13,250 Common Shares at $0.00 per share through the exercise/settlement of restricted stock units.
On February 19, 2026, he sold 6,967 Common Shares at an average price of $52.58 per share. A footnote explains that this sale was required to cover tax withholding obligations under the company’s RSU Settlement Policy and was not a discretionary trade. After these transactions, he directly held 226,106 Common Shares.
The restricted stock units were originally granted on February 18, 2022 for 53,000 Common Shares, vesting in four equal annual installments through February 18, 2026.
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported a mix of equity transactions involving company stock. On February 18, 2026, he acquired 3,825 Common Shares through the exercise and settlement of restricted stock units at a price of $0.00 per share, increasing his direct holdings to 87,227 Common Shares. On February 19, 2026, 2,112 Common Shares were sold at an average price of $52.58 per share to cover tax withholding obligations related to the RSU vesting, as required by the company’s RSU Settlement Policy and not as a discretionary trade. After these transactions, he directly owned 85,115 Common Shares.
Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd report beneficial ownership of 5,950,145 shares of CRISPR Therapeutics common stock, representing 6.2% of the class as of 12/31/2025. Orbis holds 5,934,328 shares and Allan Gray holds 15,817 shares, each with sole voting and dispositive power over its respective holdings.
Both firms are non-U.S. institutions equivalent to investment advisers and state that the securities are held in the ordinary course of business, not to change or influence control of CRISPR Therapeutics. Other persons have rights to receive dividends or sale proceeds on the shares each firm beneficially owns.
CRISPR Therapeutics describes its business as a leader in CRISPR/Cas9 gene-editing medicines, highlighted by CASGEVY, the first approved CRISPR-based therapy for severe sickle cell disease and transfusion‑dependent beta thalassemia in patients 12 and older across multiple regions.
The company outlines four core franchises: hemoglobinopathies, in vivo liver gene editing, allogeneic CAR T cell therapies for autoimmune diseases and oncology, and regenerative medicine for Type 1 diabetes. It estimates about 60,000 eligible SCD and TDT patients in key Western and Middle Eastern markets.
Pipeline updates include CTX310 in Phase 1b for cardiovascular disease, where a single-course treatment cut ANGPTL3 by up to 89%, triglycerides by up to 84%, and LDL by up to 87% in early data, and CTX611, a long‑acting siRNA Factor XI inhibitor now in Phase 2. Zugo‑cel, its next‑generation allogeneic CD19 CAR T, shows high response rates in relapsed or refractory large B‑cell lymphoma and early remission signals in systemic lupus erythematosus.
CRISPR Therapeutics reported fourth quarter and full-year 2025 results, showing early CASGEVY commercialization alongside higher losses as it invests in its pipeline. CASGEVY generated $54 million in Q4 2025 revenue and $116 million for the full year, with 64 patients infused in 2025 and 147 initiating treatment.
Cash, cash equivalents and marketable securities were $1,975.8 million as of December 31, 2025, slightly above $1,903.8 million a year earlier. Q4 2025 R&D expense rose to $83.5 million from $71.7 million, and collaboration expense jumped to $53.7 million from $10.4 million due to the absence of a prior-year cost deferral.
Net loss widened to $130.6 million for Q4 2025 versus $37.3 million a year ago, and to $581.6 million for 2025 versus $366.3 million in 2024. The company highlighted progress across in vivo liver editing, its siRNA collaboration, autoimmune and oncology CAR-T programs, and regenerative medicine, with multiple clinical and data updates expected in 2026.
Capital International Investors filed an amended Schedule 13G reporting its beneficial ownership of common stock of CRISPR Therapeutics AG. The firm is deemed to beneficially own 1,186,794 shares, representing 1.2% of the issuer’s 95,300,233 shares believed to be outstanding.
Capital International Investors reports sole voting and sole dispositive power over all reported shares and no shared power. The filer also certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of CRISPR Therapeutics AG.
CRISPR Therapeutics’ Chief Medical Officer, Naimish Patel, reported buying 1,508 common shares at $32.96 each on April 3, 2025. This direct ownership transaction brought his total reported holdings to 1,508 shares.
The filing notes this purchase was matchable under Section 16(b) with a later sale of 1,508 shares at $35.94 per share on May 29, 2025 under a mandatory “sell to cover” for a vested restricted stock unit. Patel agreed to pay CRISPR Therapeutics $4,493.84, equal to the full short-swing profit.
CRISPR Therapeutics’ Chief Financial Officer Prasad Raju reported an option exercise and share sale. On January 22, 2026, he exercised a stock option for 34,972 Common Shares at an exercise price of $45.15 per share, acquiring the same number of common shares. That same day, he sold 34,972 Common Shares at a weighted average price of $60.19 per share under a pre-arranged Rule 10b5-1 trading plan adopted on August 18, 2025. After these transactions, he directly held 6,767 Common Shares and 41,667 stock options.